Insmed Incorporated (INSM)
Nasdaq · Healthcare · Biotechnology
$103.83−6.56%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $22.7B
- Forward P/E
- 134.0
- 52-week range
- $90.39 – $212.75
- 52-week change
- −29.80%
- EPS (trailing)
- −$4.10
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $606M (+66.73%)
- Net income
- −$1.3B
- Operating margin
- −205.6%
- Diluted EPS
- −$6.42
- Free cash flow
- −$968M
From the company’s annual report on SEC EDGAR.
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension.
Headquarters: Bridgewater, United States · 1,664 employees · insmed.com